148 related articles for article (PubMed ID: 38911847)
1. Re-emergence of T lymphocyte-mediated synaptopathy in progressive multiple sclerosis.
Sanna K; Bruno A; Balletta S; Caioli S; Nencini M; Fresegna D; Guadalupi L; Dolcetti E; Azzolini F; Buttari F; Fantozzi R; Borrelli A; Stampanoni Bassi M; Gilio L; Lauritano G; Vanni V; De Vito F; Tartacca A; Mariani F; Rovella V; Musella A; Centonze D; Mandolesi G
Front Immunol; 2024; 15():1416133. PubMed ID: 38911847
[TBL] [Abstract][Full Text] [Related]
2. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
Gentile A; Musella A; Bullitta S; Fresegna D; De Vito F; Fantozzi R; Piras E; Gargano F; Borsellino G; Battistini L; Schubart A; Mandolesi G; Centonze D
J Neuroinflammation; 2016 Aug; 13(1):207. PubMed ID: 27566665
[TBL] [Abstract][Full Text] [Related]
3. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
[TBL] [Abstract][Full Text] [Related]
4. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Benedict RHB; Tomic D; Cree BA; Fox R; Giovannoni G; Bar-Or A; Gold R; Vermersch P; Pohlmann H; Wright I; Karlsson G; Dahlke F; Wolf C; Kappos L
Neurology; 2021 Jan; 96(3):e376-e386. PubMed ID: 33328324
[TBL] [Abstract][Full Text] [Related]
5. Siponimod ameliorates metabolic oligodendrocyte injury via the sphingosine-1 phosphate receptor 5.
Behrangi N; Heinig L; Frintrop L; Santrau E; Kurth J; Krause B; Atanasova D; Clarner T; Fragoulis A; Joksch M; Rudolf H; Meuth SG; Joost S; Kipp M
Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2204509119. PubMed ID: 36161894
[TBL] [Abstract][Full Text] [Related]
6. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.
Wu Q; Mills EA; Wang Q; Dowling CA; Fisher C; Kirch B; Lundy SK; Fox DA; Mao-Draayer Y;
JCI Insight; 2020 Feb; 5(3):. PubMed ID: 31935197
[TBL] [Abstract][Full Text] [Related]
7. Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke.
Vogelgesang A; Domanska G; Ruhnau J; Dressel A; Kirsch M; Schulze J
Stroke; 2019 May; 50(5):1224-1231. PubMed ID: 31009359
[TBL] [Abstract][Full Text] [Related]
8. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
Scott LJ
CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
[TBL] [Abstract][Full Text] [Related]
9. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK.
Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M
J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251
[TBL] [Abstract][Full Text] [Related]
10. Siponimod in the treatment of multiple sclerosis.
Goodman AD; Anadani N; Gerwitz L
Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
[No Abstract] [Full Text] [Related]
11. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
[TBL] [Abstract][Full Text] [Related]
12. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
Musella A; Gentile A; Guadalupi L; Rizzo FR; De Vito F; Fresegna D; Bruno A; Dolcetti E; Vanni V; Vitiello L; Bullitta S; Sanna K; Caioli S; Balletta S; Nencini M; Buttari F; Stampanoni Bassi M; Centonze D; Mandolesi G
Cells; 2020 May; 9(5):. PubMed ID: 32455907
[TBL] [Abstract][Full Text] [Related]
13. Siponimod to treat secondary progressive multiple sclerosis.
Gajofatto A; Turatti M
Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
[TBL] [Abstract][Full Text] [Related]
14. Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis.
Brand RM; Diddens J; Friedrich V; Pfaller M; Radbruch H; Hemmer B; Steiger K; Lehmann-Horn K
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34911793
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
16. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
[TBL] [Abstract][Full Text] [Related]
17. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
[TBL] [Abstract][Full Text] [Related]
18. Siponimod: First Global Approval.
Al-Salama ZT
Drugs; 2019 Jun; 79(9):1009-1015. PubMed ID: 31144287
[TBL] [Abstract][Full Text] [Related]
19. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Krasnov VS; Kolontareva YM
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
[TBL] [Abstract][Full Text] [Related]
20. miR-142-3p Is a Key Regulator of IL-1β-Dependent Synaptopathy in Neuroinflammation.
Mandolesi G; De Vito F; Musella A; Gentile A; Bullitta S; Fresegna D; Sepman H; Di Sanza C; Haji N; Mori F; Buttari F; Perlas E; Ciotti MT; Hornstein E; Bozzoni I; Presutti C; Centonze D
J Neurosci; 2017 Jan; 37(3):546-561. PubMed ID: 28100738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
